<p>ALT5 Sigma（纳斯达克代码：ALTS - 获取免费报告）在周六发布的研究报告中被华尔街 Zen 的投资分析师从 “卖出” 评级下调至 “强烈卖出” 评级。</p>
<p>另外，Weiss Ratings 在 12 月 29 日的报告中重申了对 ALT5 Sigma 股票的 “卖出（d-）” 评级。根据 MarketBeat 的数据显示，一位分析师对该股票给予了卖出评级，ALT5 Sigma 的共识评级为 “卖出”。</p>
<p><strong>阅读我们对 ALTS 的最新分析</strong></p>
<h2>ALT5 Sigma 上涨 2.4%</h2>
<p>周五，纳斯达克 ALTS 的开盘价为 0.98 美元。该公司的债务与股本比率为 0.01，流动比率为 0.79，速动比率为 0.79。ALT5 Sigma 的 12 个月低点为 0.87 美元，12 个月高点为 10.95 美元。该公司的 50 日简单移动平均线为 1.31 美元，200 日简单移动平均线为 1.72 美元。</p>
<p>ALT5 Sigma（纳斯达克代码：ALTS - 获取免费报告）最后一次发布财报是在 4 月 11 日，报告显示该季度每股收益（EPS）为（6.19 美元）。该季度的收入为 537 万美元。ALT5 Sigma 的净利润率为 133.06%，股本回报率为 8.60%。</p>
<h2>ALT5 Sigma 的机构交易</h2>
<p>几家对冲基金最近调整了对 ALTS 的持股。Balyasny Asset Management L.P.在第四季度购买了 ALT5 Sigma 的新股份，价值约为 26,000 美元。Arete Wealth Advisors LLC 在第三季度购买了 ALT5 Sigma 的新股份，价值约为 28,000 美元。Profund Advisors LLC 在第三季度购买了 ALT5 Sigma 的新股份，价值约为 28,000 美元。Victory Capital Management Inc.在第三季度购买了 ALT5 Sigma 的新股份，价值约为 33,000 美元。最后，First Citizens Bank &amp; Trust Co.在第三季度购买了 ALT5 Sigma 的新股份，价值约为 35,000 美元。6.27% 的股票由机构投资者持有。</p>
<h2>关于 ALT5 Sigma</h2>
<p>（获取免费报告）</p>
<p>ALT5 Sigma Corp.是一家临床阶段的生物制药公司，专注于识别、收购、许可、开发、合作和商业化新型非阿片类和非成瘾性疗法，以满足对疼痛和成瘾治疗的巨大未满足医疗需求。它在生物技术和回收两个领域运营。生物技术部门专注于寻找治疗导致严重疼痛的疾病的疗法，并将具有非成瘾性止痛特性的药物推向市场。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 ALT5 Sigma</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 ALT5 Sigma 吗？</h2>
<p>在你考虑 ALT5 Sigma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 ALT5 Sigma 并不在名单上。</p>
<p>虽然 ALT5 Sigma 目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ALTS

2 倍做多纳斯达克生物技术 ETF - ProShares

医药突破 ETF - ALPS

<p>华尔街禅将 ALT5 Sigma（NASDAQ:ALTS）的评级从 “卖出” 下调至 “强烈卖出”。该公司报告的净利润率为 133.06%，股本回报率为 8.60%，最近的交易价格为 0.98 美元。机构投资者持有该股票的 6.27%。该公司专注于开发非阿片类的疼痛和成瘾治疗方法。尽管评级下调，一些分析师认为其他股票可能是更好的投资选择</p>

<p>ALT5 Sigma (NASDAQ:ALTS - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a &#34;sell&#34; rating to a &#34;strong sell&#34; rating in a research report issued on Saturday.</p>
<div class="lb-trans"><p>ALT5 Sigma（纳斯达克代码：ALTS - 获取免费报告）在周六发布的研究报告中被华尔街 Zen 的投资分析师从 “卖出” 评级下调至 “强烈卖出” 评级。</p>
</div><p>Separately, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of ALT5 Sigma in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, ALT5 Sigma has a consensus rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 12 月 29 日的报告中重申了对 ALT5 Sigma 股票的 “卖出（d-）” 评级。根据 MarketBeat 的数据显示，一位分析师对该股票给予了卖出评级，ALT5 Sigma 的共识评级为 “卖出”。</p>
</div><p><strong>Read Our Latest Analysis on ALTS</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 ALTS 的最新分析</strong></p>
</div><h2>ALT5 Sigma Trading Up 2.4%</h2>
<div class="lb-trans"><h2>ALT5 Sigma 上涨 2.4%</h2>
</div><p>NASDAQ ALTS opened at $0.98 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.79 and a quick ratio of 0.79. ALT5 Sigma has a twelve month low of $0.87 and a twelve month high of $10.95. The company's 50-day simple moving average is $1.31 and its 200 day simple moving average is $1.72.</p>
<div class="lb-trans"><p>周五，纳斯达克 ALTS 的开盘价为 0.98 美元。该公司的债务与股本比率为 0.01，流动比率为 0.79，速动比率为 0.79。ALT5 Sigma 的 12 个月低点为 0.87 美元，12 个月高点为 10.95 美元。该公司的 50 日简单移动平均线为 1.31 美元，200 日简单移动平均线为 1.72 美元。</p>
</div><p>ALT5 Sigma (NASDAQ:ALTS - Get Free Report) last posted its earnings results on Saturday, April 11th. The company reported ($6.19) earnings per share (EPS) for the quarter. The firm had revenue of $5.37 million during the quarter. ALT5 Sigma had a net margin of 133.06% and a return on equity of 8.60%.</p>
<div class="lb-trans"><p>ALT5 Sigma（纳斯达克代码：ALTS - 获取免费报告）最后一次发布财报是在 4 月 11 日，报告显示该季度每股收益（EPS）为（6.19 美元）。该季度的收入为 537 万美元。ALT5 Sigma 的净利润率为 133.06%，股本回报率为 8.60%。</p>
</div><h2>Institutional Trading of ALT5 Sigma</h2>
<div class="lb-trans"><h2>ALT5 Sigma 的机构交易</h2>
</div><p>Several hedge funds have recently modified their holdings of ALTS. Balyasny Asset Management L.P. bought a new stake in shares of ALT5 Sigma during the fourth quarter valued at approximately $26,000. Arete Wealth Advisors LLC bought a new stake in shares of ALT5 Sigma during the third quarter valued at approximately $28,000. Profund Advisors LLC bought a new stake in shares of ALT5 Sigma during the third quarter valued at approximately $28,000. Victory Capital Management Inc. bought a new stake in shares of ALT5 Sigma during the third quarter valued at approximately $33,000. Finally, First Citizens Bank &amp; Trust Co. bought a new stake in shares of ALT5 Sigma during the third quarter valued at approximately $35,000. 6.27% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金最近调整了对 ALTS 的持股。Balyasny Asset Management L.P.在第四季度购买了 ALT5 Sigma 的新股份，价值约为 26,000 美元。Arete Wealth Advisors LLC 在第三季度购买了 ALT5 Sigma 的新股份，价值约为 28,000 美元。Profund Advisors LLC 在第三季度购买了 ALT5 Sigma 的新股份，价值约为 28,000 美元。Victory Capital Management Inc.在第三季度购买了 ALT5 Sigma 的新股份，价值约为 33,000 美元。最后，First Citizens Bank &amp; Trust Co.在第三季度购买了 ALT5 Sigma 的新股份，价值约为 35,000 美元。6.27% 的股票由机构投资者持有。</p>
</div><h2>About ALT5 Sigma</h2>
<div class="lb-trans"><h2>关于 ALT5 Sigma</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.</p>
<div class="lb-trans"><p>ALT5 Sigma Corp.是一家临床阶段的生物制药公司，专注于识别、收购、许可、开发、合作和商业化新型非阿片类和非成瘾性疗法，以满足对疼痛和成瘾治疗的巨大未满足医疗需求。它在生物技术和回收两个领域运营。生物技术部门专注于寻找治疗导致严重疼痛的疾病的疗法，并将具有非成瘾性止痛特性的药物推向市场。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than ALT5 Sigma</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 ALT5 Sigma</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ALT5 Sigma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 ALT5 Sigma 吗？</h2>
</div><p>Before you consider ALT5 Sigma, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 ALT5 Sigma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ALT5 Sigma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 ALT5 Sigma 并不在名单上。</p>
</div><p>While ALT5 Sigma currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 ALT5 Sigma 目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

ALT5 Sigma（NASDAQ: ALTS）在 Wall Street Zen 被下调至 “强烈卖出” 评级